Calliditas Therapeutics AB
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Calliditas Therapeutics AB
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.
Accelerated Approvals: Conversions Still Outweigh Withdrawals, But Takeda’s Exkivity Brings 2023’s Pull Count To Six
US FDA’s Oncologic Drugs Advisory Committee will convene in November for a ‘general discussion about delayed confirmatory trials’ and the ‘continued optimization of the accelerated approval process.’
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Pharmalink AB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.